Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK)
HKD 11.12
(0.18%)
HKD 11.12
(0.18%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 98.44 Million | -91.32 Million | -116.2 Million | -82.33 Million | -53.09 Million |
| Net Income | -78.73 Million | -113.55 Million | -199.68 Million | -100.46 Million | -66.64 Million |
| Depreciation & Amortization | 35.88 Million | 26.26 Million | 13.38 Million | 9.63 Million | 9.57 Million |
| Deferred income taxes | - | - | 3.84 Million | -691 Thousand | -2.72 Million |
| Stock-based compensation | 85.76 Million | 87.67 Million | 76.21 Million | 23.11 Million | 7.6 Million |
| Change in working capital | 32.78 Million | -72.53 Million | 2.83 Million | -14.23 Million | -1.84 Million |
| Other non-cash items | -77.78 Million | -19.17 Million | -12.78 Million | 306 Thousand | 946 Thousand |
| Investing Cash Flow | -206.24 Million | -95.04 Million | -1.32 Billion | -249.17 Million | -90.59 Million |
| Investments in PPE | -190.91 Million | -145.28 Million | -89.59 Million | -45.14 Million | -41.58 Million |
| Acquisitions | - | -39.69 Million | 11.48 Million | - | - |
| Investment purchases | -1.04 Billion | -3.14 Billion | -3.66 Billion | -489.2 Million | -466 Million |
| Sales/Maturities of investments | 1.02 Billion | 3.19 Billion | 2.42 Billion | 285.12 Million | 416.96 Million |
| Other Investing Activities | 8.67 Million | 39.69 Million | -11.37 Million | 41 Thousand | 22 Thousand |
| Financing Cash Flow | -11.46 Million | -30.25 Million | 2.8 Billion | 345.53 Million | 179.44 Million |
| Debt repayment | -50 Million | -4.89 Million | -35 Million | -23 Million | -15 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | -53.8 Million | -24.64 Million | -9.14 Million | - | - |
| Common Stock Issuance | - | - | 2.96 Billion | 336.37 Million | - |
| Other Financing Activities | -1.25 Million | -722 Thousand | -114.26 Million | 32.16 Million | 194.44 Million |
| Accounts receivables | -170 Thousand | -574 Thousand | -329 Thousand | 884 Thousand | -525 Thousand |
| Accounts payables | - | 574 Thousand | 329 Thousand | -884 Thousand | 525 Thousand |
| Inventory | -47.29 Million | -61.97 Million | -28.27 Million | -19.03 Million | -2.3 Million |
| Other working capital | 43.85 Million | -10.56 Million | 31.11 Million | 4.8 Million | 461 Thousand |
| Cash at beginning of period | 1.2 Billion | 1.41 Billion | 59.55 Million | 46.13 Million | 10.48 Million |
| Cash at end of period | 1.08 Billion | 1.2 Billion | 1.41 Billion | 59.55 Million | 46.13 Million |
| Capital Expenditure | -190.91 Million | -145.28 Million | -89.59 Million | -45.14 Million | -41.58 Million |
| Effect of forex changes on cash | 540 Thousand | 3.56 Million | -6.46 Million | -601 Thousand | -109 Thousand |
| Net cash flow / Change in cash | -118.72 Million | -213.05 Million | 1.35 Billion | 13.42 Million | 35.65 Million |
| Free Cash Flow | -92.47 Million | -236.6 Million | -205.8 Million | -127.47 Million | -94.67 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 34.43 Million | 34.43 Million | -78.73 Million | -21.61 Million | -21.61 Million | -17.75 Million |
| Depreciation & Amortization | 9.04 Million | 9.04 Million | 35.88 Million | 9.75 Million | 9.75 Million | 8.18 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 4.65 Million | 4.65 Million | 85.76 Million | 27.88 Million | 27.88 Million | 14.99 Million |
| Change in working capital | - | - | 32.78 Million | -1.8 Million | -1.8 Million | - |
| Other non-cash items | 3.89 Million | 3.89 Million | -77.78 Million | 44.25 Million | 44.25 Million | -14.68 Million |
| Investing Cash Flow | -332.38 Million | -332.38 Million | -206.24 Million | -158.62 Million | -158.62 Million | 55.5 Million |
| Investments in PPE | -60.95 Million | -60.95 Million | -190.91 Million | -38.21 Million | -38.21 Million | -57.24 Million |
| Acquisitions | - | - | - | - | - | 30.53 Thousand |
| Investment purchases | - | - | -1.04 Billion | - | - | -572.85 Million |
| Sales/Maturities of investments | - | - | 1.02 Billion | - | - | 818.84 Million |
| Other Investing Activities | -271.42 Million | -271.42 Million | 8.67 Million | -120.41 Million | -120.41 Million | 112.75 Million |
| Financing Cash Flow | 2.81 Million | 2.81 Million | -11.46 Million | -8.25 Million | -8.25 Million | 2.52 Million |
| Debt repayment | - | - | -50 Million | - | - | -10.17 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -7.98 Million | -7.98 Million | -53.8 Million | -26.83 Million | -26.83 Million | -62.5 Thousand |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 10.79 Million | 10.79 Million | -1.25 Million | 18.58 Million | 18.58 Million | 2.58 Million |
| Accounts receivables | - | - | -170 Thousand | -85 Thousand | -85 Thousand | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | -47.29 Million | -23.64 Million | -23.64 Million | - |
| Other working capital | - | - | 43.85 Million | 21.92 Million | 21.92 Million | - |
| Cash at beginning of period | - | - | 1.2 Billion | - | - | 1.35 Billion |
| Cash at end of period | -276.98 Million | -276.98 Million | 1.08 Billion | -110.14 Million | -110.14 Million | 1.41 Billion |
| Capital Expenditure | -60.95 Million | -60.95 Million | -190.91 Million | -38.21 Million | -38.21 Million | -57.24 Million |
| Effect of forex changes on cash | 568 Thousand | 568 Thousand | 540 Thousand | -1.75 Million | -1.75 Million | 2.02 Million |
| Net cash flow / Change in cash | -276.98 Million | -276.98 Million | -118.72 Million | -110.14 Million | -110.14 Million | 56.79 Million |
| Free Cash Flow | -8.93 Million | -8.93 Million | -92.47 Million | 20.27 Million | 20.27 Million | -66.51 Million |
6403
RBBN
FLCX
TIKK
HECOF
IFUS